Supplier to the healthcare industry, Gerresheimer, has been commissioned to produce plastic containers which will contain dexamethasone as the active ingredient.
The plastic can DB39 from Gerresheimer in which the dexamethasone tablets for the treatment of seriously ill Covid-19 patients are filled.
Recently, the medical journal and other media reported that the World Health Organisation (WHO) had called for an increase in the production of the active ingredient dexamethasone. This is because according to a study, the active ingredient can reduce the mortality of people who are seriously ill with Covid-19.
Jens Friis, vice president Europe and Latin America at Primary Plastic Packaging, responsible for sales, commented: "Thanks to globally standardised processes and technologies, we are able to produce flexibly, locally, and sustainably. This also includes optimising procurement and transport routes for our customers.
"For the packaging of dexamethasone, we supply 100ml drug cans with closures."
Friis explained how the first mould was successfully transferred to the production site in Vaerloese, Denmark in December 2019, in order to be able to supply local European markets in an optimal way.